{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03607890",
            "orgStudyIdInfo": {
                "id": "J18102"
            },
            "secondaryIdInfos": [
                {
                    "id": "IRB00173534",
                    "type": "OTHER",
                    "domain": "JHMI IRB"
                },
                {
                    "id": "P50CA062924",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/P50CA062924"
                }
            ],
            "organization": {
                "fullName": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "briefTitle": "Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor",
            "officialTitle": "Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "study-of-nivolumab-and-relatlimab-in-advanced-mismatch-repair-deficient-cancers-resistant-to-prior-pd-l-inhibitor"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2018-11-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-07-24",
            "studyFirstSubmitQcDate": "2018-07-24",
            "studyFirstPostDateStruct": {
                "date": "2018-07-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-09",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Bristol-Myers Squibb",
                    "class": "INDUSTRY"
                },
                {
                    "name": "National Cancer Institute (NCI)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy."
        },
        "conditionsModule": {
            "conditions": [
                "Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy",
                "MSI-H Tumors"
            ],
            "keywords": [
                "Relatlimab",
                "Nivolumab",
                "Immunotherapy",
                "Anti - PD-1",
                "Anti - LAG-3",
                "Antibodies",
                "MSI",
                "MMR deficient",
                "Microsatellite instability"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 42,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Nivolumab and Relatlimab",
                    "type": "EXPERIMENTAL",
                    "description": "480mg/160mg (co-administered)",
                    "interventionNames": [
                        "Drug: Nivolumab",
                        "Drug: Relatlimab"
                    ]
                },
                {
                    "label": "Cohort 2: Nivolumab and Relatlimab",
                    "type": "EXPERIMENTAL",
                    "description": "480mg/960mg or 480mg/160mg (sequential administration)",
                    "interventionNames": [
                        "Drug: Nivolumab",
                        "Drug: Relatlimab"
                    ]
                },
                {
                    "label": "Cohort 3: Nivolumab and Relatlimab",
                    "type": "EXPERIMENTAL",
                    "description": "480mg/480mg (sequential administration)",
                    "interventionNames": [
                        "Drug: Nivolumab",
                        "Drug: Relatlimab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).",
                    "armGroupLabels": [
                        "Cohort 1: Nivolumab and Relatlimab"
                    ],
                    "otherNames": [
                        "anti-PD-1, OPDIVO"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Relatlimab",
                    "description": "Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).",
                    "armGroupLabels": [
                        "Cohort 1: Nivolumab and Relatlimab"
                    ],
                    "otherNames": [
                        "BMS-986016"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).",
                    "armGroupLabels": [
                        "Cohort 2: Nivolumab and Relatlimab"
                    ],
                    "otherNames": [
                        "anti-PD-1, OPDIVO"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Relatlimab",
                    "description": "Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).",
                    "armGroupLabels": [
                        "Cohort 2: Nivolumab and Relatlimab"
                    ],
                    "otherNames": [
                        "BMS-986016"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Nivolumab",
                    "description": "Patients will receive treatment every 28 days for up to 2 years. Nivolumab will be administered IV on day 1 (28 day cycle).",
                    "armGroupLabels": [
                        "Cohort 3: Nivolumab and Relatlimab"
                    ],
                    "otherNames": [
                        "anti-PD-1, OPDIVO"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Relatlimab",
                    "description": "Patients will receive treatment every 28 days up to 2 years. Relatlimab will be administered IV on day 1 (28 day cycle).",
                    "armGroupLabels": [
                        "Cohort 3: Nivolumab and Relatlimab"
                    ],
                    "otherNames": [
                        "BMS-986016"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)",
                    "timeFrame": "4 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants experiencing study drug-related toxicities",
                    "timeFrame": "4 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u226518 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Have metastatic or locally advanced mismatch repair deficient/MSI-H disease.\n* Patients must have received prior PD-1/PD-L1 inhibitor therapy\n* Patients with the presence of at least one measurable lesion.\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study - specified laboratory tests.\n* Documented left ventricular ejection fraction (LVEF) \u2265 50% - 6 month prior to drug administration.\n* Must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Known history or evidence of brain metastases.\n* Require any antineoplastic therapy.\n* History of prior treatment with anti-LAG3.\n* Had chemotherapy, radiation, or steroids within 14 days prior to study treatment.\n* Had any investigational cytotoxic drug within 4 weeks prior to study treatment.\n* Have received any investigational drugs, a live vaccine, any allergen hyposensitization therapy, growth factors or major surgery within 28 days prior to study treatment.\n* Major surgery\n* Hypersensitivity reaction to any monoclonal antibody.\n* Has an active known or suspected autoimmune disease.\n* Has a diagnosis of immunodeficiency.\n* Prior tissue or organ allograft or allogeneic bone marrow transplantation.\n* Requires daily supplemental oxygen\n* History of interstitial lung disease.\n* Significant heart disease\n* History of encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent.\n* Infection with HIV or hepatitis B or C at screening.\n* Has an active infection.\n* Unable to have blood drawn.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Prior life-threatening toxicity to anti-PD-1, anti-PD-L1, anti-PD-L2,or anti-CTLA4\n* Woman who are pregnant or breastfeeding.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Colleen Apostal, RN",
                    "role": "CONTACT",
                    "phone": "410-614-3644",
                    "email": "GIClinicaltrials@jhmi.edu"
                },
                {
                    "name": "Joann Santmyer, RN",
                    "role": "CONTACT",
                    "phone": "410-614-3644",
                    "email": "GIClinicaltrials@jhmi.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Dung Le, MD",
                    "affiliation": "Johns Hopkins Medical Institution",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Sidney Kimmel Comprehensive Cancer Center",
                    "status": "RECRUITING",
                    "city": "Baltimore",
                    "state": "Maryland",
                    "zip": "21231",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Trish Brothers, RN",
                            "role": "CONTACT",
                            "phone": "410-614-3644",
                            "email": "GIClinicaltrials@jhmi.edu"
                        },
                        {
                            "name": "Joann Santmyer",
                            "role": "CONTACT",
                            "phone": "410-614-3644",
                            "email": "GIClinicaltrials@jhmi.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.29038,
                        "lon": -76.61219
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M27510",
                    "name": "Microsatellite Instability",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077594",
                    "term": "Nivolumab"
                },
                {
                    "id": "C000721227",
                    "term": "Relatlimab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M1854",
                    "name": "Nivolumab",
                    "asFound": "Technique",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M354150",
                    "name": "Relatlimab",
                    "asFound": "Episodic",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}